We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MRP:JSEMr Price Group Limited Analysis

Data as of 2026-03-14 - not real-time

ZAC 16,749.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Mr Price Group is trading at ZAc 16,749, well under its 20‑day (ZAc 17,401) and 50‑day (ZAc 17,190) simple moving averages and far below the 200‑day average (ZAc 20,034), indicating a short‑term price weakness. The bearish MACD (-82 on the line, -92 histogram) and a sub‑50 RSI (41.7) reinforce the downside bias, while the stock sits close to its technical support at ZAc 16,527 and faces resistance near ZAc 18,631. Volatility is elevated at roughly 28% over the past 30 days, though the beta of 0.36 suggests the share moves less than the broader market.
Fundamentally, the company delivers solid performance: revenue grew 5.2% YoY to ZAc 41.4 bn, margins are healthy (gross 41.9%, operating 11.5%, profit 9.0%) and ROE is an impressive 28.5%. Cash flow is robust (operating cash ZAc 8.5 bn, free cash ZAc 6.6 bn) and the dividend yield of 5.47% with a 64% payout ratio appears sustainable. Valuation metrics signal upside – a DCF fair value of ZAc 41,238 implies >50% upside, the mean analyst target (ZAc 25,393) and median target (ZAc 22,000) sit well above the current price, and the forward PE of 10.3 is attractive despite an unusually high price‑to‑book ratio.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near technical support
  • Bearish MACD and sub‑50 RSI
  • Undervaluation indicated by DCF and analyst targets

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong earnings growth and high ROE
  • Attractive dividend yield with sustainable payout
  • Significant upside potential from fair‑value models

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Consistent cash generation and low beta
  • Robust balance sheet despite moderate debt
  • Long‑term undervaluation and dividend income

Key Metrics & Analysis

Financial Health

Revenue Growth5.20%
Profit Margin9.00%
P/E Ratio11.9
ROE28.55%
ROA11.10%
Debt/Equity61.77
P/B Ratio323.5
Op. Cash FlowZAC8.5B
Free Cash FlowZAC6.6B

Technical Analysis

TrendNeutral
RSI41.7
SupportZAC 16,527.00
ResistanceZAC 18,631.00
MA 20ZAC 17,401.15
MA 50ZAC 17,190.26
MA 200ZAC 20,034.25
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Fair ValueZAC 41,237.83
Target PriceZAC 25,393.10
Upside/Downside51.61%
GradeUndervalued
TypeBlend
Dividend Yield5.47%

Risk Assessment

Beta0.36
Volatility27.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.